Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I Study of Ascending Doses of MMV390048 in Healthy Adult Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02230579
Recruitment Status : Completed
First Posted : September 3, 2014
Results First Posted : October 29, 2018
Last Update Posted : July 17, 2019
Sponsor:
Collaborator:
University of Cape Town
Information provided by (Responsible Party):
Medicines for Malaria Venture

Brief Summary:

This is a first-in-human study of MMV390048. The study will evaluate the safety, tolerability and pharmacokinetic properties of escalating single and multiple doses of MMV390048 when administered to healthy male volunteers and female volunteers of non-childbearing potential.

In addition, the effect of food on the pharmacokinetics and tolerability of MMV390048 will be investigated.


Condition or disease Intervention/treatment Phase
Malaria Drug: MMV390048 5mg Drug: MMV390048 20mg Drug: MMV390048 40mg Drug: MMV390048 80mg Drug: MMV390048 120mg Drug: Placebo to match MMV390048 Phase 1

Detailed Description:

The study is a single centre, double-blind, randomised, placebo-controlled, ascending dose study in healthy male and female volunteers (of non-childbearing potential) aged 18 to 55 years.

The study will be divided into two parts. The first part will comprise up to seven fasted cohorts (8 to 10 volunteers in each) that will receive a single, ascending dose (SAD) of MMV390048 to assess its safety, tolerability and pharmacokinetic profile. The starting dose administered to the first cohort will be 5 mg. An additional cohort (cohort 8, re-using volunteers from one of the previous cohorts) will receive a single dose of MMV390048 in a fed state to evaluate the effect of food on the pharmacokinetics and tolerability of the compound.

The data obtained from each cohort during the SAD part of the study will undergo a formal review by the Safety Review Team (SRT). Should the safety profile of the compound be deemed acceptable, and the pharmacokinetic parameters indicate that acceptable levels of the drug to elicit a pharmacodynamic response can be achieved in human plasma, the study will then proceed to the second part.

During the second part of the study volunteers will receive multiple, ascending doses (MAD) of MMV390048 to assess the pharmacokinetics, safety and tolerability following multiple oral doses. Up to three cohorts of eight volunteers each will be enrolled into this part of the study. Each volunteer will receive three consecutive daily doses of MMV390048.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Single Centre, Two-part, Double-blind, Randomized, Placebo-controlled Phase I Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Doses of MMV390048 in Healthy Adult Volunteers
Study Start Date : May 2014
Actual Primary Completion Date : February 2015
Actual Study Completion Date : February 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malaria

Arm Intervention/treatment
Experimental: Cohort SAD1 Fasted
Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
Drug: MMV390048 5mg
Supplied as "powder in bottle" formulation for reconstitution pre-dose
Other Name: MMV390048

Drug: Placebo to match MMV390048
Supplied as "powder in bottle" formulation for reconstitution pre-dose
Other Name: Placebo

Experimental: Cohort SAD2 Fasted
Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
Drug: MMV390048 20mg
Supplied as "powder in bottle" formulation for reconstitution pre-dose.
Other Name: MMV390048

Drug: Placebo to match MMV390048
Supplied as "powder in bottle" formulation for reconstitution pre-dose
Other Name: Placebo

Experimental: Cohort SAD3 Fasted
Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
Drug: MMV390048 40mg
Supplied as "powder in bottle" formulation for reconstitution pre-dose
Other Name: MMV390048

Drug: Placebo to match MMV390048
Supplied as "powder in bottle" formulation for reconstitution pre-dose
Other Name: Placebo

Experimental: Cohort SAD4 Fasted
Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
Drug: MMV390048 80mg
Supplied as "powder in bottle" formulation for reconstitution pre-dose
Other Name: MMV390048

Drug: Placebo to match MMV390048
Supplied as "powder in bottle" formulation for reconstitution pre-dose
Other Name: Placebo

Experimental: Cohort SAD5 Fasted
Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
Drug: MMV390048 120mg
Supplied as "powder in bottle" formulation for reconstitution pre-dose
Other Name: MMV390048

Drug: Placebo to match MMV390048
Supplied as "powder in bottle" formulation for reconstitution pre-dose
Other Name: Placebo

Experimental: Cohort SAD6 Fed
Cohort SAD6, reusing volunteers from one of the previous cohorts, will receive a single dose in a fed state to evaluate the effect of food on the pharmacokinetics and tolerability
Drug: MMV390048 40mg
Supplied as "powder in bottle" formulation for reconstitution pre-dose
Other Name: MMV390048

Drug: Placebo to match MMV390048
Supplied as "powder in bottle" formulation for reconstitution pre-dose
Other Name: Placebo




Primary Outcome Measures :
  1. Number of Participants With Adverse Events [ Time Frame: up to D29 or longer according to half life ]
    Subject will be in-house up to D3, and then have a follow up visit at the site on D5, 7, 10, 14, 19, 26, 29 or longer according to half life

  2. Area Under the Plasma Concentration Versus Time Curve (AUC) of MMV390048 [ Time Frame: 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, 216, 312, 432, 600, 672 hours post-dose ]
    Pk blood collection - additional PK point may be planned final visit depending on emerging PK data, unnecessary PK points could be eliminated for the latter cohorts Investigate the effect of food on the pharmacokinetic and tolerability of the investigational drug in cohort 4 and 8

  3. Half-life of MMV390048 [ Time Frame: 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, 216, 312, 432, 600, 672 hours post-dose ]
    Pk blood collection Investigate the effect of food on the pharmacokinetic and tolerability of the investigational drug in cohort 4 and 8


Secondary Outcome Measures :
  1. Determine ex Vivo Efficacy (IC50) [ Time Frame: up to 144 hr post dose ]
    Blood collection to determine efficacy of investigational drug against parasites using an ex vivo malaria assay - this was done only for cohort 3 The experimentally obtained bioassay IC50 values were determined and compared to IC50 obtained with reference serum sample spiked with a known amount of MMV390048 titrated into the P. falciparum assay.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • written informed consent
  • Male and female (of non-childbearing potential); age 18 to 55 years, in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening
  • Hematology, clinical chemistry and urinalysis results at screening that are within the local laboratory reference range or, if outside the range, not clinically significant. AST, ALT, lactate dehydrogenase, total bilirubin, haptoglobin and hemoglobin must be within the normal reference ranges
  • Body weight at least 50kg and body mass index within 18 to 32kg/m2
  • Good peripheral venous access
  • Able to communicate well with the investigator, to understand and comply with the requirements of the study
  • Agree to stay in contact with the study site for the duration of the study, provide updated contact information as necessary, and have no current plans to move away from the study area for the duration of the study

Exclusion Criteria:

  • Any acute illness upon admission to the unit on Day -1 or prior to dosing on Day 1
  • Use of any other investigational drug within 30 days or five half-lives (whichever is longer) prior to the first dose of MMV390048
  • history of hypersensitivity to any drugs
  • history of anaphylaxis or severe allergic reaction
  • Resting vital signs at either screening or baseline outside the defined ranges
  • Orthostatic changes in blood pressure and heart rate measurements greater than: 20 mmHg drop in systolic blood pressure; 10 mmHg drop in diastolic blood pressure; 20 beats per minute increase in heart rate
  • history of clinically significant ECG abnormalities, or any of the defined ECG abnormalities at either screening or baseline
  • History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past five years, regardless of whether there is evidence of local recurrence or metastases
  • Pregnant or nursing (lactating) women
  • Women of child-bearing potential
  • males physiologically capable of conceiving offspring UNLESS the volunteer agrees to use condoms and ensure that his partner(s) is either not of child-bearing potential or uses a highly effective method of contraception for the entire duration of the study and for twelve weeks following the last study drug administration
  • Smokers (use of tobacco products in the previous three months)
  • Use of any prescription drugs, herbal supplements, over--the--counter medication or dietary supplements (vitamins included) within four weeks prior to initial dosing
  • Intake of grapefruit, grapefruit juice or other products containing grapefruit within 28 days of the first drug administration of the study drug
  • Excessive intake of caffeine drinks or energy drinks within 48 hours before admission defined as more than three 250 ml cups of coffee a day
  • Donation or loss of 400 ml or more of blood within eight weeks prior to screening or initial dosing
  • Plasma donation (>100 ml) within 60 days prior to first dosing
  • Hemoglobin levels below 12.5 g/dl (males) or 11.5 g/dl (females) at screening
  • Haptoglobin levels outside the reference range
  • Positive direct anti-globulin test
  • Liver enzymes other than ALT, AST and lactate dehydrogenase elevated ≥1.5 x ULN within two weeks prior to initial dosing
  • history of autonomic dysfunction within 3 years and/or recurrent history
  • History of immunodeficiency diseases, including a confirmed positive HIV test result
  • Positive Hepatitis B surface antigen or Hepatitis C antibody test result
  • History of recurrent infection
  • history of endocrine disease, in particular adrenal disorders such as Cushing's syndrome or Addison's disease, or diabetes mellitus
  • history of Gilbert's Syndrome
  • history of photosensitivity
  • history of any food allergy
  • Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardise the safety of the volunteer or the objectives of the study
  • History or presence of impaired renal function as indicated by clinically significantly abnormal creatinine or urea values, or abnormal urinary constituents
  • History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of such abuse as indicated by the tests and laboratory assays at screening and/or baseline
  • Any clinically significant mental disorder that could limit the validity of informed consent or the volunteer's ability to comply with protocol requirements

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02230579


Locations
Layout table for location information
South Africa
Cinical Pharmacology, University of Cape Town
Cape Town, South Africa
Sponsors and Collaborators
Medicines for Malaria Venture
University of Cape Town
Investigators
Layout table for investigator information
Principal Investigator: Karen Barnes, Prof University of Cape Town
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Medicines for Malaria Venture
ClinicalTrials.gov Identifier: NCT02230579    
Other Study ID Numbers: MMV_MMV390048_14_01
First Posted: September 3, 2014    Key Record Dates
Results First Posted: October 29, 2018
Last Update Posted: July 17, 2019
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Medicines for Malaria Venture:
safety
tolerability
malaria
Additional relevant MeSH terms:
Layout table for MeSH terms
Malaria
Protozoan Infections
Parasitic Diseases